SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology
-$0.02 today
- Market cap
- $262.16M
- Beta
- 0.53
- P/E (TTM)
- 3.0
- EPS (TTM)
- -$0.16
Volume 1.75M
Average 0.76M
Returns on capital
SAB Biotherapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
8.8%
avg 20.0%
ROIC
-30.0%
avg -44.3%
ROA
7.7%
avg -27.4%
Analysis
ROE is currently the strongest return metric at 8.8% versus its period average of 20.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Samuel J. Reich | CEO & Director | USD 846.46K | 51 | 4.80M | 5.28% |
Alexandra Kropotova | Executive Vice President & Chief Medical Officer | USD 832.25K | 53 | 41.85K | 0.05% |
Eddie Joe Sullivan | Co-Founder, President & Director | USD 746.5K | 59 | 3.00M | 3.30% |
Lucy To | Executive Vice President & Chief Financial Officer | USD 684.03K | 40 | 2.40M | 2.64% |
Christoph Bausch | Executive Vice President & Chief Operating Officer | USD 609K | 55 | — | — |
Angie Parizek | Senior Vice President of Clinical Operations | — | — | — | — |
Hua Wu | Senior Vice President of Product Development | — | — | 4.65K | <0.01% |
Carlos N. Carillo | Senior Vice President of Regulatory Affairs | — | — | 17.68K | 0.02% |
Catherine DeRose | Vice President of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | -13.5% (5yr)6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Net Income at -13.5% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does SAB Biotherapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about SABS's management, answered from reported figures.
Who manages SABS?
SAB Biotherapeutics, Inc. (SABS) lists 9 active executives. The top listed executive is Samuel J. Reich, CEO & Director.
Are SABS insiders buying or selling?
Recent insider activity shows net buying of $377.21M.
Continue the stock analysis
Jump to another research area for this company.